Crohn's Disease: Symptoms, Causes, Types & Integrative Treatment NYC

Crohn's Disease

Crohn's Disease: Symptoms, Types, Causes & Integrative Treatment in NYC

Crohn’s disease is a chronic inflammatory bowel disease driven by a dysregulated immune response against the gut microbiome producing cycles of intestinal damage, nutritional depletion, and systemic inflammation that extend far beyond the digestive tract. For many patients, years of unpredictable flares, urgent bathroom trips, and the emotional weight of a condition that controls daily life precede a diagnosis, let alone a treatment plan that actually addresses the underlying drivers.

3.1M

Americans living with IBD

20–40

Peak age of diagnosis (years)

70%

Patients with anaemia during active disease

30+

Extra-intestinal manifestations documented

Medically reviewed by Dr. Rashmi Gulati, MD — Medical Director, Patients Medical.

Board-certified integrative medicine physician.

Clinical Definition

Crohn’s disease (ICD-10: K50) is a chronic, immune-mediated inflammatory bowel disease characterised by transmural, granulomatous inflammation with the potential to affect any part of the gastrointestinal tract from mouth to anus, with predilection for the terminal ileum and proximal colon, presenting as patchy skip lesions and capable of producing strictures, fistulae, and abscesses as complications of full-thickness bowel wall involvement. The condition is pathophysiologically distinct from ulcerative colitis and is driven by aberrant Th1 and Th17 immune responses against gut-resident commensal bacteria — principally mediated through TNF-α, IL-12, IL-23, and IL-17 — in individuals carrying susceptibility variants across more than 240 identified genetic loci, most notably NOD2/CARD15. A functional medicine evaluation examines the environmental, microbiological, nutritional, and lifestyle factors that initiate and perpetuate the immune dysregulation, enabling a precision approach to remission induction and maintenance.

Key Symptoms

Chronic abdominal pain and cramping
Persistent or bloody diarrhoea
Unintentional weight loss
Extreme fatigue and exhaustion
Perianal fistulae or abscesses
Mouth sores and aphthous ulcers

Primary Causes

Genetic susceptibility (NOD2/CARD15 variants)
Gut microbiome dysbiosis
Dysregulated Th1/Th17 immune response
Intestinal permeability ("leaky gut")
Prior gastrointestinal infections
Smoking, NSAIDs, dietary triggers

Treatment Approach

Anti-inflammatory nutrition (SCD / low-FODMAP)
Gut microbiome restoration
Intestinal barrier repair (L-glutamine, zinc)
Nutrient repletion (B12, D3, iron, folate)
Botanical anti-inflammatories (curcumin, Boswellia)
Coordination with gastroenterology for biologics if needed

What Is Crohn's Disease?

Crohn’s disease is not simply a “sensitive stomach.” It is a systemic inflammatory condition rooted in immune dysregulation — and understanding it clearly is the first step toward managing it effectively.

Crohn’s disease is a chronic inflammatory bowel disease (IBD) that causes the immune system to attack the lining of the gastrointestinal tract, producing inflammation that can occur anywhere from the mouth to the anus. Most commonly, Crohn’s affects the terminal ileum — the final section of the small intestine — and portions of the colon. Unlike most inflammatory conditions that affect only a surface layer, Crohn’s is transmural: the inflammation penetrates through all layers of the bowel wall, from the innermost mucosa through to the outermost serosa. This full-thickness involvement is what distinguishes it from ulcerative colitis and explains why Crohn’s can lead to complications like fistulae (abnormal tunnels), strictures (narrowings), and abscesses that do not occur in surface-only inflammation.

The biological mechanism at the core of Crohn’s disease is an aberrant immune response against the body’s own gut microbiome. In healthy individuals, the immune system maintains tolerance to the trillions of commensal bacteria that inhabit the intestine. In Crohn’s, this tolerance breaks down — most commonly in genetically susceptible individuals carrying variants in the NOD2/CARD15 gene (which regulates bacterial pattern recognition) and across more than 240 additional susceptibility loci identified through genome-wide association studies. When these genetic vulnerabilities intersect with environmental triggers — dietary antigens, infections, dysbiosis, stress, or environmental toxins — the immune system mounts an exaggerated Th1 and Th17 inflammatory response characterised by the overproduction of cytokines including TNF-α, IL-12, IL-23, and IL-17. These cytokines drive ongoing mucosal damage, further compromise the intestinal barrier, and fuel a self-perpetuating cycle of inflammation.

From a functional medicine perspective, genetic susceptibility explains who is at risk, but the environmental and lifestyle factors that activate those genes determine who actually develops disease — and how severely. Identifying which specific drivers are active in each patient — whether gut dysbiosis, intestinal permeability, food sensitivities, nutritional deficiencies, or chronic stress — creates an opportunity to intervene at the source rather than simply suppressing downstream immune activity. Crohn’s disease affects approximately 780,000 Americans, with an estimated global incidence rising sharply in industrialised nations, particularly among younger populations. It affects men and women in roughly equal proportions and most commonly first presents between the ages of 20 and 40, though onset in adolescence and later adulthood is not uncommon.

Terminal Ileum

The last 15–20 cm of the small intestine and the most common site of Crohn’s involvement. It is responsible for absorbing vitamin B12, bile salts, and fat-soluble vitamins deficiencies that almost universally accompany terminal ileal disease.

Intestinal Mucosa & Tight Junctions

The one-cell-thick epithelial lining of the bowel is held together by tight junction proteins including claudin and occludin. In Crohn’s, TNF-α and IL-13 directly disrupt these proteins, increasing intestinal permeability and allowing bacterial antigens to fuel systemic inflammation.

Gut-Associated Lymphoid Tissue (GALT)

The largest immune organ in the body, the GALT including Peyer’s patches in the ileum is where tolerance to gut bacteria is established. In Crohn’s, dysregulated GALT activity and Th1/Th17 skewing produce the sustained inflammatory response that characterises the disease.

Signs & Symptoms of Crohn's Disease

Crohn’s disease presents across multiple body systems because intestinal inflammation triggers systemic immune activation meaning symptoms extend far beyond the digestive tract and often precede or overshadow the GI manifestations.

Gastrointestinal Symptoms

Chronic Abdominal Pain and Cramping

Typically located in the right lower quadrant (terminal ileal disease) or diffusely across the abdomen, driven by transmural inflammation, bowel wall oedema, and smooth muscle spasm.

Persistent Diarrhoea

Often watery, urgent, and nocturnal; may contain blood or mucus when colonic mucosa is actively inflamed and ulcerated.

Rectal Bleeding and Blood in Stool

Present in approximately 45% of Crohn's patients with colonic involvement; contributes to iron-deficiency anaemia and is an important disease activity marker.

Nausea, Vomiting, and Reduced Appetite

Inflammatory cytokines, particularly TNF-α and IL-6, suppress appetite centrally while bowel obstruction from strictures can cause postprandial nausea and vomiting.

Perianal Disease (Fistulae, Fissures, Abscesses)

Occurs in up to 30% of Crohn's patients; transmural inflammation tunnels through to adjacent structures, creating perianal fistulae and abscesses requiring both medical and surgical management.

Mouth Ulcers (Aphthous Stomatitis)

Recurring painful oral ulcers reflect the disease's capacity to affect any mucosal surface; often flare in parallel with intestinal disease activity.

Systemic & Energy Symptom

Profound Fatigue

Reported by up to 80% of patients, fatigue in Crohn's is driven by active inflammation (IL-6 and TNF-α directly reduce energy metabolism), anaemia, nutritional deficiency, and disrupted sleep from nocturnal symptoms.

Fever During Flares

Cytokine-mediated pyrexia — particularly from IL-1β and TNF-α — is common during active disease; high fever may indicate abscess or serious infection.

Unintentional Weight Loss and Malnutrition

A catabolic state driven by inflammatory cytokines, combined with malabsorption and reduced appetite, causes muscle wasting and progressive weight loss even in patients with seemingly adequate food intake.

Delayed Growth and Development (Paediatric)

Children with Crohn's experience growth faltering due to chronic undernutrition, elevated inflammatory cytokines suppressing growth hormone signalling, and corticosteroid side effects.

Anaemia and Pallor

Iron-deficiency anaemia from blood loss, anaemia of chronic disease from IL-6-driven hepcidin upregulation, and B12 deficiency from terminal ileal disease all coexist and compound one another.

Musculoskeletal & Skin Symptoms

Peripheral Arthropathy

Joint pain and swelling — typically asymmetrical, migratory, and affecting large joints like knees and ankles — correlates with intestinal disease activity in Type 1 arthropathy and follows an independent course in Type 2.

Erythema Nodosum

Tender, raised, red nodules typically on the shins; reflects immune complex deposition and correlates with intestinal flare activity, resolving as intestinal disease is controlled.

Pyoderma Gangrenosum

A rare but severe neutrophilic dermatosis producing painful skin ulcers; a recognised extra-intestinal manifestation of IBD requiring specialised dermatological management.

Axial Arthropathy (Sacroiliitis, Ankylosing Spondylitis)

Inflammatory back pain from sacroiliitis or ankylosing spondylitis associated with Crohn's does not correlate with intestinal activity and requires independent rheumatological evaluation and management.

Clubbing of the Fingers

Digital clubbing is a recognised but poorly understood extra-intestinal manifestation of Crohn's disease, reflecting chronic hypoxia and inflammatory vascular remodelling.

Neurological, Eye & Hormonal Symptoms

Uveitis and Episcleritis

Ocular inflammation — presenting as painful red eyes (episcleritis) or deep eye pain with photophobia (uveitis) — is among the most common extra-intestinal manifestations, affecting 2–5% of Crohn's patients.

Cognitive Impairment and Brain Fog

Pro-inflammatory cytokines cross the blood-brain barrier and disrupt dopaminergic and serotonergic neurotransmission; IDO pathway activation diverts tryptophan away from serotonin toward neurotoxic kynurenine metabolites.

Depression and Anxiety

Psychiatric comorbidity is present in 20–30% of IBD patients — two to three times the population rate — driven by both the psychological impact of chronic illness and direct inflammatory effects on the brain via the gut-brain axis.

Menstrual Irregularities

Chronic inflammation and malnutrition disrupt the hypothalamic-pituitary-ovarian axis; active Crohn's is associated with reduced fertility and increased pregnancy complications.

Nephrolithiasis (Kidney Stones)

Terminal ileal disease increases oxalate absorption from the colon due to unbound oxalate binding calcium; combined with chronic dehydration from diarrhoea, this markedly increases calcium oxalate kidney stone risk.

The 4 Main Types of Crohn's Disease

Crohn’s disease is classified by the location of inflammation along the gastrointestinal tract, and this location determines symptom pattern, complication risk, nutritional impact, and the optimal treatment approach — making accurate typing essential before any intervention.

01 Ileocolitis

Most Common — 40% of Cases

Ileocolitis is the most prevalent form of Crohn’s disease, affecting the terminal ileum and portions of the colon simultaneously. Patients typically experience right lower quadrant pain, diarrhoea, and significant malabsorption of vitamin B12, bile salts, and fat-soluble vitamins. Weight loss and nutritional deficiencies are particularly prominent in this form. The terminal ileum is the critical site for B12 absorption via cubilin receptors, so ileocolitis almost invariably produces B12 deficiency over time. Strictures at the ileocaecal valve are a frequent complication. This form is most likely to respond to a Specific Carbohydrate Diet combined with targeted nutrient repletion.

02 Jejunoileitis

Pure Small Bowel — 30% of Cases

Jejunoileitis involves patchy inflammation in the jejunum and/or ileum (the upper and mid portions of the small intestine) without colonic involvement. Because the small bowel is the primary site of nutrient absorption, this form carries the most severe risk of global malnutrition, including deficiencies in iron, zinc, folate, fat-soluble vitamins, and all macronutrients. Patients often experience severe postprandial pain — leading to deliberate food restriction — compounding nutritional depletion. Fistulae between adjacent small bowel loops are a recognised complication. Elemental or semi-elemental nutrition support may be required to maintain nutritional status during acute disease.

03 Crohn's Colitis (Granulomatous Colitis)

Colonic Only — 20% of Cases

Crohn’s colitis is confined to the colon and is the form most easily confused with ulcerative colitis in clinical presentation — both produce bloody diarrhoea, abdominal cramping, and urgency. Key distinguishing features include the presence of skip lesions (normal bowel between inflamed segments), transmural rather than superficial inflammation on biopsy, and granuloma formation on histopathology. Perianal disease is more common in colonic Crohn’s than in the other forms. Extra-intestinal manifestations — particularly erythema nodosum and peripheral arthropathy — are especially prevalent with colonic involvement. Nutritional deficiencies in this form tend to be less severe than small bowel disease, though anaemia from blood loss remains common.

04 Fistulising / Penetrating Crohn's

Complex / Penetrating — Up to 20% at 10 years

This behavioural classification — rather than an anatomical type — describes Crohn’s disease that has progressed to transmural penetration through the bowel wall, forming fistulae (abnormal connections between bowel loops, bowel and skin, or bowel and bladder), abscesses, and inflammatory masses. The Montreal Classification distinguishes inflammatory (B1), stricturing (B2), and penetrating (B3) disease behaviour, and these can co-occur. Penetrating disease develops in approximately 20% of patients within 10 years of diagnosis, reflecting the progressive nature of untreated or undertreated transmural inflammation. Surgical drainage and biologic therapy (anti-TNF agents such as infliximab) are frequently required, though functional medicine optimisation of the intestinal environment plays a critical role in reducing fistula recurrence.

Causes & Risk Factors for Crohn's Disease

Crohn’s disease results from the convergence of multiple interacting factors — genetic susceptibility provides the substrate, but environmental, microbial, dietary, and lifestyle factors pull the trigger. No single cause explains all cases, which is precisely why a root-cause approach is essential for effective treatment.

01

NOD2/CARD15 Gene Variants

Variants in the NOD2 gene — which encodes a bacterial pattern recognition receptor — are the strongest single genetic risk factor for Crohn’s, increasing risk 20–40 fold in homozygous carriers and primarily driving ileocaecal disease.

02

Gut Microbiome Dysbiosis

Crohn’s is consistently associated with reduced diversity and depletion of keystone anti-inflammatory species — particularly Faecalibacterium prausnitzii and Roseburia — alongside overgrowth of adherent-invasive E. coli (AIEC) strains that colonise the ileal mucosa.

03

Increased Intestinal Permeability

Disruption of tight junction proteins (claudin-1, occludin, ZO-1) allows bacterial antigens and endotoxins to translocate across the epithelial barrier, triggering and perpetuating the immune response that drives mucosal inflammation.

04

Prior Enteric Infections

Salmonella, Campylobacter, Clostridium difficile, and norovirus infections significantly increase post-infectious IBD risk; molecular mimicry and persistent microbiome disruption are proposed mechanisms for triggering the disease.

05

Cigarette Smoking

Smoking is the strongest modifiable environmental risk factor for Crohn’s, approximately doubling disease risk, accelerating disease progression, increasing fistula formation, and significantly reducing response to medical therapy — a stark contrast to its paradoxically protective role in ulcerative colitis.

06

Chronic NSAID Use

Non-steroidal anti-inflammatory drugs — including ibuprofen and naproxen — inhibit COX-1-dependent prostaglandin synthesis in the intestinal mucosa, directly compromising the protective epithelial barrier and precipitating or worsening IBD flares.

07

Ultra-Processed Diet and Food Additives

Emulsifiers (carboxymethylcellulose, polysorbate-80), maltodextrin, and artificial sweeteners have been shown in animal and epidemiological studies to disrupt the intestinal mucus layer, promote AIEC colonisation, and trigger intestinal inflammation.

08

Antibiotic Exposure in Childhood

Meta-analyses show that antibiotic exposure before age 5 significantly increases IBD risk, most likely through disruption of critical early microbiome colonisation and impairment of normal immune tolerance development during a sensitive developmental window.

09

Dysregulated Th1/Th17 Immune Axis

In genetically susceptible individuals, the adaptive immune system is skewed toward excessive Th1 (IFN-γ, TNF-α) and Th17 (IL-17, IL-22) responses, driving chronic intestinal inflammation in the absence of effective regulatory T-cell counter-regulation.

10

Family History and Genetic Loading

First-degree relatives of Crohn’s patients have a 5–20% lifetime risk of developing IBD; having a sibling with Crohn’s carries the highest familial risk, underscoring the polygenic nature of the condition across more than 240 identified susceptibility loci.

11

Chronic Psychological Stress

HPA-axis dysregulation and sympathetic nervous system dominance produced by chronic stress alter gut motility, increase intestinal permeability via corticotropin-releasing factor (CRF) receptors on mast cells, and modulate mucosal immune activity via the gut-brain axis.

12

Vitamin D Insufficiency

Vitamin D3 acts as a key immune modulator in the intestinal mucosa promoting tolerogenic dendritic cell activity and regulatory T-cell differentiation; deficiency is nearly universal in active Crohn’s and is independently associated with increased disease activity and flare frequency.

Crohn's Disease vs. Related Conditions

Crohn’s disease shares overlapping symptoms with several other gastrointestinal conditions, and distinguishing between them requires specific testing not just symptom assessment. The following table maps the key clinical differences.

Feature	Crohn’s Disease	Ulcerative Colitis	Irritable Bowel Syndrome (IBS)	Coeliac Disease
Location of Involvement	Anywhere from mouth to anus; skip lesions; terminal ileum most common	Colon only; continuous from rectum proximally	No structural involvement; functional disorder	Small intestine primarily; duodenum and jejunum
Depth of Inflammation	Transmural (full bowel wall thickness)	Mucosal and submucosal only	No inflammation — normal histology	Villous atrophy in mucosa
Key Biomarker	ASCA positive; elevated fecal calprotectin; elevated CRP	pANCA positive; elevated fecal calprotectin; elevated CRP	Normal CRP; normal fecal calprotectin	Anti-tTG IgA; total IgA; anti-DGP
Hallmark Symptom	Right lower quadrant pain; perianal fistulae; weight loss	Bloody diarrhoea; rectal urgency; tenesmus	Bloating; altered bowel habit; pain relieved by defaecation	Diarrhoea; bloating; dermatitis herpetiformis; fatigue
Best Diagnostic Test	Colonoscopy with terminal ileal intubation + MR enterography	Colonoscopy with full biopsy mapping	Rome IV criteria (diagnosis of exclusion)	Duodenal biopsy (Marsh scoring) + serology
Curable by Surgery?	No — recurs in remaining bowel	Yes — colectomy curative	N/A — no surgical indication	N/A — managed by strict gluten-free diet
Comorbid Overlap	PSC, spondyloarthropathy, uveitis, erythema nodosum	PSC (more common than Crohn’s), pyoderma gangrenosum	Anxiety, depression, fibromyalgia, SIBO	Thyroid autoimmunity, T1DM, other autoimmune conditions

Key clinical note: Crohn’s disease and ulcerative colitis cannot always be distinguished on initial evaluation — approximately 10–15% of IBD cases are classified as “IBD unclassified” (IBDU) or “indeterminate colitis.” Repeat endoscopy, serological panels (ASCA/pANCA), and advanced imaging (MR enterography) over time typically clarify the diagnosis.

Crohn's Disease and Functional Medicine: Is There More Than Suppression?

Crohn’s disease itself is universally recognised by conventional medicine. The substantive clinical debate is about treatment goals — whether the objective should be symptomatic control alone, or the deeper resolution of the environmental and biological drivers perpetuating the disease.

01 Conventional Gastroenterology's Position

Crohn's disease is incurable; the goal is remission induction and maintenance
Immunosuppression (corticosteroids, thiopurines, methotrexate) and biologics (anti-TNF, anti-integrin, anti-IL-12/23) are the primary treatment tools
Diet plays a supportive but not primary therapeutic role in standard guidelines
Mucosal healing on endoscopy is the benchmark of remission
Regular surveillance colonoscopy is essential due to increased colorectal cancer risk

02 Functional Medicine's Perspective

Remission without addressing root causes is inherently fragile and drug-dependent
Gut microbiome restoration, intestinal barrier repair, and nutritional optimisation directly address upstream disease drivers
Diet particularly the Specific Carbohydrate Diet and the Crohn's Disease Exclusion Diet has emerging trial evidence comparable to corticosteroids for mild-moderate disease induction
Nutritional deficiencies (B12, D3, zinc, iron, folate) perpetuate disease course and must be corrected as part of treatment, not as an afterthought
The gut-brain axis, HPA-axis dysregulation, and psychological stress are active disease perpetuators that conventional protocols rarely address systematically

Patients Medical’s position: We work collaboratively with our patients’ gastroenterologists and do not recommend abandoning biologic or immunomodulator therapy in patients with moderate-to-severe Crohn’s. Our integrative approach layers functional medicine investigation and intervention — gut microbiome analysis, nutritional repletion, dietary modification, barrier repair, and stress physiology — on top of, not instead of, evidence-based conventional treatment. The goal is to achieve the deepest possible remission with the lowest necessary immunosuppressive burden, and to sustain it long-term.

How We Diagnose Crohn's Disease in NYC

Diagnosing and monitoring Crohn’s disease requires a combination of endoscopic, histological, imaging, and laboratory testing. Our functional medicine evaluation adds several critical layers that standard gastroenterology alone does not typically address providing a far more complete picture of what is driving your disease.

01 Fecal Calprotectin and Lactoferrin

Fecal calprotectin is a neutrophil-derived protein released during active intestinal inflammation and is the most accurate non-invasive marker of mucosal inflammation in IBD. Levels above 250 µg/g strongly indicate active inflammatory bowel disease and correlate closely with endoscopic disease activity, while levels below 50 µg/g effectively rule out significant mucosal inflammation. We use serial fecal calprotectin measurements to monitor treatment response without repeated endoscopy.

02 High-Sensitivity CRP, ESR, and Full Inflammatory Panel

C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are elevated during active Crohn’s and provide systemic markers of inflammatory burden. High-sensitivity CRP (hsCRP) is particularly valuable for monitoring low-grade inflammation in patients in apparent clinical remission. We pair these with a full inflammatory cytokine panel where indicated, including TNF-α, IL-6, and IL-1β, to characterise the inflammatory phenotype and guide targeted intervention.

03 ASCA / pANCA Serology Panel (IBD Serology 7)

The ASCA (anti-Saccharomyces cerevisiae antibody) and pANCA (perinuclear anti-neutrophil cytoplasmic antibody) panel helps differentiate Crohn’s disease from ulcerative colitis and from non-IBD causes of bowel inflammation. ASCA IgA/IgG positivity with pANCA negativity has approximately 60–70% sensitivity and 90% specificity for Crohn’s. The extended IBD Serology 7 panel adds OmpC and anti-flagellin (CBir1) antibodies, improving diagnostic accuracy in indeterminate cases.

04 Comprehensive Gut Microbiome Analysis (GI-MAP or Genova GI Effects)

A comprehensive stool analysis using quantitative PCR (GI-MAP) or culture-independent profiling (Genova GI Effects) identifies specific microbial patterns associated with Crohn’s disease — including Faecalibacterium prausnitzii deficiency, adherent-invasive E. coli (AIEC) presence, reduced butyrate-producing species, and commensal overgrowth patterns. This test guides targeted probiotic and prebiotic interventions and evaluates markers of intestinal permeability and immune activation (secretory IgA, zonulin, anti-gliadin antibodies).

05 Comprehensive Nutritional Panel

Nutritional deficiencies are near-universal in Crohn’s disease and significantly impact disease course, treatment response, and quality of life. Our comprehensive nutritional assessment measures serum B12, methylmalonic acid (functional B12 marker), folate, vitamin D (25-OH), iron studies with ferritin, zinc, magnesium, albumin, and fat-soluble vitamins A, E, and K. Micronutrient testing (SpectraCell or NutrEval) provides the most complete picture of intracellular nutrient status. These findings directly shape the repletion protocol.

Does This Sound Like You?

Check all that apply to your current experience:

Chronic or recurrent abdominal pain, cramping, or urgency
Diarrhoea that persists or recurs despite dietary changes
Unintentional weight loss or difficulty maintaining weight
Fatigue that doesn't improve with rest or sleep
Blood or mucus in the stool
Perianal pain, discharge, or recurring fistulae
Joint pain, skin rashes, or eye inflammation alongside GI symptoms
Recurring mouth ulcers or oral inflammation
Symptoms that flare with stress or certain foods

Crohn's Disease Treatment at Patients Medical NYC

Our integrative approach to Crohn’s disease combines the best of functional medicine investigation and intervention with evidence-based gastroenterology — targeting the biological drivers of your disease rather than indefinitely suppressing the immune response that results from them.

Therapeutic Nutrition & Elimination Protocols

Diet is one of the most powerful modulators of intestinal inflammation and microbiome composition. We use structured dietary protocols — including the Specific Carbohydrate Diet (SCD), the Crohn’s Disease Exclusion Diet (CDED), and personalised low-FODMAP approaches — alongside comprehensive food sensitivity testing to identify and eliminate dietary triggers while ensuring nutritional adequacy. The CDED has demonstrated clinical remission rates comparable to corticosteroids in mild-moderate paediatric Crohn’s in randomised trial data, and we apply its principles across our adult patients.

SCD Protocol

CDED

]Low-FODMAP

Elimination Diet

Food Sensitivity Panel

Gut Microbiome Restoration

Crohn’s disease is consistently associated with reduced microbial diversity and depletion of keystone butyrate-producing species. We use comprehensive stool microbiome analysis (GI-MAP) to identify specific dysbiosis patterns and design targeted interventions: clinical-grade probiotics including Lactobacillus rhamnosus GG, Bifidobacterium longum, and Saccharomyces boulardii (the only probiotic with consistent IBD trial evidence); prebiotic fibre protocols using partially hydrolysed guar gum and inulin-type fructans; and — where indicated — herbal antimicrobials to reduce pathogenic colonisation.

GI-MAP Testing

Prebiotic Protocol

Saccharomyces boulardii

Lactobacillus GG

Intestinal Barrier Repair Programme

Increased intestinal permeability is both a consequence and a cause of Crohn’s inflammation — creating a self-perpetuating cycle. Our barrier repair programme uses a combination of L-glutamine (the primary fuel for enterocytes), zinc carnosine (demonstrated to improve tight junction protein expression in clinical trials), collagen peptides, deglycyrrhizinated liquorice (DGL), and aloe vera gel to support mucosal regeneration. Intestinal permeability is measured before and after treatment using the lactulose/mannitol ratio urinary test.

L-Glutamine

Zinc Carnosine

Collagen Peptides

DGL

Permeability Testing

Targeted Nutrient Repletion Therapy

Nutritional deficiencies are present in virtually every patient with active Crohn’s disease and significantly impair immune function, tissue repair, cognitive performance, and energy production. Our repletion programme is guided by comprehensive laboratory testing and commonly includes: vitamin B12 (as hydroxocobalamin injections or sublingual methylcobalamin where terminal ileal absorption is impaired), vitamin D3 at therapeutic doses (typically 5,000–10,000 IU with K2), iron infusion therapy (when oral supplementation is not tolerated or insufficient), folate, zinc picolinate, and omega-3 fatty acids (EPA/DHA 3–4g daily).

B12 Injections

Vitamin D3/K2

Iron Infusion

IV Nutrient Therapy

Zinc Picolinate

Botanical Anti-Inflammatory Support

Several plant-derived compounds have demonstrated meaningful anti-inflammatory activity in Crohn’s disease through well-characterised mechanisms. Curcumin (from turmeric, 1–2g daily as phosphatidylcholine complex for absorption) inhibits NF-κB and TNF-α; multiple trials demonstrate additive benefit to conventional therapy. Boswellia serrata extract (AKBA fraction) inhibits 5-lipoxygenase, reducing leukotriene production that drives intestinal inflammation. Aloe vera gel has mucosal soothing and anti-inflammatory properties with some trial evidence in IBD. Slippery elm and marshmallow root provide mucilage that protects the intestinal mucosal surface.

Curcumin Phosphatidylcholine

Boswellia AKBA

Aloe Vera Gel

Slippery Elm

Gut-Brain Axis & Stress Physiology Support

The gut-brain axis is not peripheral to Crohn’s management — it is central to it. Chronic stress, HPA-axis dysregulation, and sympathetic nervous system dominance directly increase intestinal permeability via CRF receptor activation on mast cells, alter gut motility, and shift the microbiome in dysbiotic directions. Our approach assesses adrenal function via cortisol/DHEA-S profiling, addresses sleep architecture, and implements evidence-based mind-body protocols including diaphragmatic breathing, progressive muscle relaxation, and low-dose cognitive behavioural therapy for IBD (CBT-IBD). We also assess and address depression and anxiety as co-conditions requiring direct treatment.

HPA-Axis Assessment

CBT-IBD

Cortisol/DHEA-S Panel

Adrenal Support

Breathwork

What to Expect: Treatment Timeline

Weeks 1–4	Initial symptom stabilisation; dietary protocol implementation; lab results reviewed; targeted supplementation begun. Many patients notice reduced urgency and improved stool consistency within the first 3–4 weeks.
Weeks 6–12	Measurable reduction in fecal calprotectin and CRP expected; significant improvement in fatigue, abdominal pain, and bowel habit. Microbiome seeding and barrier repair protocols are well-established by this point.
Months 3–6	Full inflammatory marker normalisation; nutritional deficiencies being corrected; introduction of maintenance-phase dietary and supplement protocol. Extra-intestinal symptoms (joint pain, fatigue, skin) typically resolve significantly.
Month 12–18	Deep mucosal healing assessed by repeat colonoscopy; long-term remission maintenance protocol established; monitoring schedule set for ongoing biomarker surveillance.

Lifestyle Practices for Crohn's Disease Recovery

Lifestyle interventions are not optional adjuncts in Crohn’s management — they are active therapeutic tools that directly modulate intestinal inflammation, gut-brain signalling, and disease course. These recommendations are mechanism-specific, not generic wellness advice.

Daily Parasympathetic Activation (10–20 minutes of structured breathwork)

The sympathetic nervous system directly activates corticotropin-releasing factor (CRF) receptors on intestinal mast cells, increasing permeability and triggering mast cell degranulation. Counter this with daily 4-7-8 breathing (inhale 4 counts, hold 7, exhale 8) or diaphragmatic breathing — physiologically proven to shift autonomic tone toward parasympathetic dominance and reduce intestinal mast cell reactivity within 6–8 weeks of consistent practice.

Low-to-Moderate Intensity Exercise (150 minutes/week, avoiding high-intensity during flares)

Regular moderate exercise — walking, swimming, yoga, cycling — reduces systemic inflammatory markers (CRP, IL-6) and supports microbiome diversity by increasing butyrate-producing bacterial species. Critically, high-intensity exercise during active disease increases intestinal permeability through endotoxaemia and should be avoided during flares. Aim for 30 minutes of light-moderate activity 5 days per week, shifting intensity up only during sustained remission.

Sleep Optimisation (7–9 hours; address nocturnal disruption from bowel symptoms)

Chronic sleep deprivation increases gut permeability, elevates circulating CRP and IL-6, and drives HPA-axis dysregulation — all of which perpetuate Crohn's inflammation. Address sleep-disrupting nocturnal symptoms with your physician; implement strict sleep hygiene including darkness, 18–20°C room temperature, and cessation of screens 60 minutes before bed. Low-dose melatonin (0.5–3mg at bedtime) has anti-inflammatory properties in the gut and supports sleep quality without dependency.

Smoking Cessation (Non-Negotiable for Crohn's Patients)

Smoking is the most impactful modifiable risk factor for Crohn's disease — it doubles disease risk, accelerates the transition to fistulising disease, reduces mucosal healing, and significantly impairs response to biologic therapy. Unlike ulcerative colitis, there is no "protective" paradox in Crohn's. Cessation within 6–12 months is associated with a measurable reduction in disease activity and complication rates. If you smoke and have Crohn's, stopping is the single most important lifestyle change you can make.

Targeted Hydration Strategy (Electrolyte-Replete Fluids, 2.5–3L Daily)

Chronic diarrhoea creates significant fluid and electrolyte losses — particularly sodium, potassium, magnesium, and bicarbonate. Plain water is insufficient for rehydration during active disease. Use an oral rehydration approach: water with added sea salt, potassium-rich coconut water, or a glucose-electrolyte solution (e.g. DripDrop, Precision Hydration). Avoid caffeinated beverages and alcohol, which increase intestinal motility and permeability. Adequate hydration also reduces oxalate kidney stone risk — a recognised Crohn's complication.

Sunlight Exposure and Vitamin D Optimisation (Target 25-OH-D: 60–80 ng/mL)

Vitamin D3 functions as a critical immunomodulator in the intestinal mucosa — promoting tolerogenic dendritic cell activity, supporting regulatory T-cell differentiation, and directly suppressing the Th17 pathway that drives Crohn's inflammation. Most Crohn's patients are significantly deficient. Aim for 15–20 minutes of direct midday skin sun exposure daily when possible, supplemented with therapeutic-dose vitamin D3 (typically 5,000–10,000 IU daily with vitamin K2 as MK-7) to achieve serum 25-OH-D of 60–80 ng/mL. Check levels every 3–4 months during repletion.

Diet & Nutrition Guide for Crohn's Disease

Diet does not cause Crohn’s disease, but it profoundly shapes the intestinal environment modulating microbiome composition, mucosal inflammation, intestinal permeability, and symptom intensity. The right dietary approach is one of the most powerful interventions available.

The single most important dietary principle for Crohn's disease:

Eliminate ultra-processed foods, industrial emulsifiers (carboxymethylcellulose, polysorbate-80), and refined carbohydrates that feed pathogenic bacteria and disrupt the intestinal mucus layer — before any other dietary change. Evidence shows these substances directly promote adherent-invasive E. coli colonisation and mucosal inflammation independently of caloric content or food sensitivity.

Eat — Foods That Support Remission

Cooked and peeled vegetables: easier to digest; provide polyphenols that feed butyrate-producing bacteria without the fibre load of raw vegetables during flares.
Wild-caught oily fish (salmon, mackerel, sardines): richest dietary source of EPA and DHA, omega-3 fatty acids that directly inhibit TNF-α production and reduce mucosal prostaglandin E2.
Bone broth: provides glycine, proline, and hydroxyproline peptides that support intestinal epithelial cell regeneration and mucosal healing.
Well-cooked eggs: complete protein source with high digestibility; phospholipids support mucosal membrane integrity.
Ripe bananas and melons: low-fibre, easily tolerated fruit sources providing potassium and simple carbohydrates without fermentable residue.
Fermented foods (yoghurt, kefir, miso): when tolerated, these deliver live Lactobacillus and Bifidobacterium strains that support mucosal immunity; introduce gradually during remission.
Turmeric and ginger (in cooking): curcumin (turmeric) and gingerols inhibit NF-κB and TNF-α; incorporate into meals daily as culinary anti-inflammatories.
White rice and well-cooked oats: low-residue, easily digested carbohydrate sources that are well-tolerated even during active disease without provoking inflammation.
Avocado: rich in oleic acid (anti-inflammatory), potassium, and monounsaturated fats; well-tolerated and nutrient-dense even during symptomatic periods.

Avoid — Foods That Worsen Inflammation

Ultra-processed foods with emulsifiers: carboxymethylcellulose and polysorbate-80 directly disrupt intestinal mucus layer integrity and promote AIEC colonisation in experimental models.
Raw high-fibre vegetables (broccoli, cabbage, kale) during flares: insoluble fibre increases intestinal transit and gas production; can mechanically irritate inflamed mucosa and worsen symptoms.
Alcohol: increases intestinal permeability, disrupts tight junction proteins, alters gut microbiome within hours of consumption, and interferes with methotrexate and other IBD medications.
NSAIDs and aspirin: COX-1 inhibition directly compromises the prostaglandin-dependent mucosal barrier; even short-term use can trigger IBD flares. Use paracetamol for pain relief instead.
Spicy foods (during active disease): capsaicin activates TRPV1 receptors on intestinal nociceptors, increasing pain sensitivity and possibly mast cell degranulation in already-inflamed tissue.
High-fat fried foods: increase intestinal permeability and promote bacterial lipopolysaccharide (LPS) absorption, driving systemic endotoxaemia and amplifying intestinal immune activation.
Refined sugar and high-fructose corn syrup: feed pathogenic gut bacteria, promote intestinal dysbiosis, and drive systemic inflammation via AGE formation and NLRP3 inflammasome activation.
Dairy products (for lactase-deficient patients): terminal ileal disease commonly causes secondary lactase deficiency; undigested lactose produces severe bloating, cramping, and diarrhoea, worsening symptom burden.

Related & Overlapping Conditions

Crohn’s disease rarely exists in isolation — it commonly co-occurs with or is confused for several related conditions, all of which we evaluate and treat at Patients Medical.

Ulcerative Colitis

The most closely related IBD condition; shares immune mechanisms, biomarkers, and many treatments with Crohn’s but is confined to the colon and has distinct histological and clinical features. Distinguishing between them is clinically critical as it determines surgical eligibility and long-term management strategy.

Coeliac Disease

An autoimmune condition triggered by gluten that causes small intestinal villous atrophy, producing malabsorption similar to Crohn’s. Coeliac and Crohn’s can coexist and should be assessed simultaneously in patients with small bowel symptoms; both share HLA-DQ2/DQ8 genetic risk and intestinal permeability as a shared mechanism.

Irritable Bowel Syndrome (IBS)

IBS is a functional bowel disorder without structural inflammation and is diagnostically distinct from Crohn’s — but up to 30% of IBD patients in remission also meet IBS diagnostic criteria, suggesting shared gut-brain axis dysfunction, visceral hypersensitivity, and microbiome disruption as overlapping mechanisms.

Chronic Fatigue Syndrome (ME/CFS)

Profound fatigue, post-exertional malaise, and cognitive impairment in Crohn’s can meet criteria for ME/CFS, particularly in patients with persistently active disease. Shared mechanisms include HPA-axis dysregulation, mitochondrial dysfunction, cytokine-driven neuroinflammation, and gut-brain axis disruption.

Ankylosing Spondylitis / Axial Spondyloarthropathy

Crohn’s is a recognised trigger and comorbidity of axial spondyloarthropathy, sharing HLA-B27 genetic risk and IL-17/IL-23 pathway dysregulation. Up to 10% of Crohn’s patients have subclinical sacroiliitis on MRI, and overt ankylosing spondylitis co-occurs at rates significantly above the general population.

Anaemia and Iron Deficiency

Iron deficiency anaemia is the most common systemic complication of Crohn’s, present in up to 70% of patients with active disease through blood loss, impaired iron absorption, and hepcidin-driven iron sequestration. Untreated anaemia significantly worsens fatigue, cognitive function, and quality of life independently of bowel symptom control.

When to See a Doctor About Crohn's Disease

Crohn’s disease is frequently under-diagnosed — on average, patients live with symptoms for 3–5 years before receiving a correct diagnosis. If any of the following apply to you, a comprehensive evaluation is not optional — it is overdue.

Seek a functional medicine evaluation if you experience any of the following:

Abdominal pain or cramping that recurs over months despite standard treatment
Unexplained weight loss of more than 5% body weight in 3–6 months
Extreme fatigue that does not improve with rest and disrupts daily function
Skin rashes or eye redness accompanying bowel symptoms
Family history of IBD in a first-degree relative

Diarrhoea more than 3 times daily, persisting beyond 4 weeks
Blood or dark mucus in the stool on more than one occasion
Joint pain or swelling occurring alongside digestive symptoms
Recurring perianal pain, swelling, or discharge
Diagnosed IBS that has not responded to standard dietary and symptomatic management

🚨 Seek immediate emergency evaluation if you experience:

Severe, sudden-onset abdominal pain with board-like rigidity (possible perforation)
Significant rectal bleeding producing haemodynamic instability
High fever (above 39°C / 102°F) with severe abdominal pain
Signs of bowel obstruction: complete cessation of bowel movements, distension, vomiting

What Our Patients Say About Crohn's Disease Treatment

Patient experiences are individual and results vary. Names have been changed to protect privacy. These testimonials reflect personal experiences and do not constitute medical guarantees.

"I had been on three different biologics over eight years, and while they controlled the worst of my symptoms, I was still exhausted all the time, my joints ached, and I felt like I was just managing to exist rather than living. Dr. Gulati found that I had severe B12 deficiency from terminal ileal damage, significant vitamin D insufficiency, and a microbiome almost completely lacking in Faecalibacterium prausnitzii. Six months into the protocol — dietary changes, targeted supplements, and the microbiome programme — my fecal calprotectin dropped from 420 to 58. I felt genuinely well for the first time in a decade."

"After my Crohn's diagnosis at 24, I spent years being told that diet 'doesn't really matter much' and to 'just take the medication.' What nobody told me was that I was severely malnourished — my zinc was almost undetectable, my iron was critically low, and my vitamin D was 14. Once we addressed those deficiencies and I implemented the Crohn's Disease Exclusion Diet, my flares dropped from monthly to twice a year. My gastroenterologist was able to step down my immunosuppression. I wish I'd come here years earlier."

"The perianal disease was the most distressing part for me — the fistulae, the recurring infections, the embarrassment and pain. My gastroenterologist was doing their best but the only tools were antibiotics and surgery. What Patients Medical added was the gut microbiome testing that showed massive pathogenic overgrowth of E. coli and almost no protective species. The targeted probiotic, prebiotic, and barrier repair protocol — alongside the curcumin and Boswellia — transformed my quality of life. The perianal disease has been in remission for 18 months now."

Explore Our Blog For More Insights

Frequently Asked Questions About Crohn's Disease

What is Crohn's disease and how is it different from other bowel conditions?

Crohn’s disease is a chronic inflammatory bowel disease (IBD) that causes transmural — meaning full-thickness — inflammation anywhere along the gastrointestinal tract, from the mouth to the anus. Unlike ulcerative colitis, which is confined to the inner lining of the colon, Crohn’s can affect the entire bowel wall and any segment of the GI tract, most commonly the terminal ileum (the last section of the small intestine) and the colon.

This transmural nature means Crohn’s can lead to complications that ulcerative colitis cannot, including fistulae (abnormal tunnels between bowel loops or skin), abscesses, and strictures (narrowings that can cause bowel obstruction). Unlike irritable bowel syndrome (IBS), which is a functional disorder without structural inflammation, Crohn’s disease is associated with objective biomarker evidence of inflammation — elevated fecal calprotectin, elevated CRP, and findings on colonoscopy or imaging.

It is driven by a dysregulated immune response against normal gut bacteria in individuals with genetic susceptibility, triggered and perpetuated by environmental factors including diet, stress, prior infections, and gut microbiome imbalance. From a functional medicine perspective, identifying which triggers are active in each patient — rather than simply suppressing the immune response — is fundamental to achieving and maintaining remission.

How long does Crohn's disease treatment and recovery take?

Crohn’s disease is a chronic, relapsing condition, meaning recovery is not a single event but an ongoing process of achieving remission, maintaining mucosal healing, and reducing flare frequency over time. The timeline for response depends heavily on disease severity, the location of involvement, and the treatments used.

With a functional medicine integrative approach, most patients begin noticing symptom improvement — less urgency, reduced bloating, more stable stool — within 6 to 12 weeks of implementing dietary changes and targeted supplementation. Objective markers like fecal calprotectin and CRP typically normalise within 3 to 6 months if the protocol is well-matched to the individual. Deep mucosal healing, which is the gold standard of remission in IBD, requires consistent maintenance and is typically assessed by repeat endoscopy at 12 to 18 months.

Patients with more severe disease, fistulising or penetrating behaviour, or a long history of untreated inflammation may require longer timelines and coordinated gastroenterology care including biologics. The most important insight from functional medicine is that the goal is not just remission — it is a remission that can be sustained without indefinite immunosuppression. Long-term follow-up monitoring with biomarkers is essential to catch early signs of flare before they become clinically significant.

What tests diagnose Crohn's disease — and what does functional medicine add?

The conventional diagnosis of Crohn’s disease is established through a combination of endoscopy (colonoscopy with terminal ileal intubation), histopathology (biopsy showing granulomatous transmural inflammation), and cross-sectional imaging (MR enterography or CT enterography) to assess small bowel involvement and complications. Blood tests including elevated C-reactive protein, elevated ESR, anaemia, and low albumin support the diagnosis. ASCA serology is approximately 60–70% sensitive and 90% specific for Crohn’s.

A functional medicine evaluation adds several critical layers. Fecal calprotectin is used not just for diagnosis but for monitoring mucosal inflammation non-invasively over time. Comprehensive stool microbiome analysis identifies specific dysbiosis patterns — deficiencies in keystone species like Faecalibacterium prausnitzii and overgrowth of pathogenic organisms — that perpetuate inflammation.

Intestinal permeability testing (lactulose/mannitol ratio) quantifies how much the gut barrier has been compromised. Nutritional testing assesses for deficiencies in B12, iron, vitamin D, folate, and zinc, which are almost universally present in active Crohn’s. Identifying these specific patterns allows a precision approach that standard gastroenterology alone does not address.

Can Crohn's disease cause weight loss, anaemia, and malnutrition?

Yes — malnutrition, unintentional weight loss, and anaemia are among the most clinically significant and underappreciated consequences of Crohn’s disease, present even in patients whose gastrointestinal symptoms appear controlled. There are multiple mechanisms driving this.

First, active intestinal inflammation dramatically impairs nutrient absorption, particularly in the terminal ileum, where vitamin B12 and bile salts are absorbed. Terminal ileal Crohn’s is therefore almost always associated with B12 deficiency and bile acid malabsorption causing fat-soluble vitamin losses (A, D, E, K). Second, chronic diarrhoea causes direct losses of minerals including zinc, magnesium, and potassium. Third, pro-inflammatory cytokines — particularly TNF-α and IL-6 — suppress appetite and increase resting metabolic rate, creating a catabolic state that causes muscle wasting even when caloric intake is maintained.

Iron-deficiency anaemia from chronic intestinal blood loss is present in up to 70% of patients with active Crohn’s. A functional medicine assessment specifically screens for all of these nutritional deficiencies and builds a targeted repletion protocol, which often has a significant impact on energy, cognitive function, and disease course.

What is the difference between Crohn's disease and ulcerative colitis?

Crohn’s disease and ulcerative colitis (UC) are both forms of inflammatory bowel disease (IBD), and they share many features — chronic abdominal symptoms, elevated inflammatory markers, and immune dysregulation — but they differ in critical ways that affect diagnosis, complications, and treatment.

Ulcerative colitis is confined strictly to the colon and always begins in the rectum, spreading continuously proximally. The inflammation in UC is limited to the mucosal and submucosal layers — it does not penetrate the full bowel wall. Crohn’s disease, by contrast, can affect any part of the GI tract from mouth to anus, often involves skip lesions (patches of inflamed bowel separated by normal tissue), and is transmural — meaning inflammation involves the full thickness of the bowel wall.

This transmural inflammation is why Crohn’s causes complications like fistulae, abscesses, and strictures that are rare in UC. A key diagnostic distinction is that pANCA positivity is more characteristic of UC, while ASCA positivity is more characteristic of Crohn’s. From a treatment perspective, UC can potentially be cured by surgical removal of the colon (colectomy), whereas Crohn’s cannot be cured by surgery and can recur in any remaining bowel segment.

How does Crohn's disease affect mental health, energy, and quality of life?

The impact of Crohn’s disease extends far beyond the gastrointestinal tract and profoundly affects mental health, cognitive function, energy, and overall quality of life. Depression and anxiety affect 20–30% of patients with IBD — rates two to three times higher than the general population — driven both by the psychological burden of an unpredictable, stigmatised chronic illness and by direct biological mechanisms.

Pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) cross the blood-brain barrier and directly alter neurotransmitter metabolism, reducing serotonin production and increasing IDO pathway activation, which can cause depression and anxiety regardless of psychosocial factors. The gut-brain axis — mediated through the vagus nerve, gut-derived serotonin (90% of serotonin is produced in the gut), and the enteric nervous system — is significantly disrupted in Crohn’s, contributing to mood dysregulation, heightened pain sensitivity, and cognitive impairment often described as brain fog.

Chronic fatigue is reported by up to 80% of patients and persists even in remission, driven by ongoing low-grade inflammation, mitochondrial dysfunction, nutritional deficiencies, and disrupted sleep from nocturnal symptoms. A functional medicine approach addresses these systemic effects directly — treating the gut-brain connection, repleting nutrients critical for neurotransmitter synthesis, and supporting HPA-axis resilience — rather than addressing mental health and GI health as separate problems.

What supplements and natural treatments support Crohn's disease recovery?

Several evidence-supported supplements and nutritional interventions play a meaningful role in managing Crohn’s disease, particularly in reducing inflammation, repairing the gut barrier, and correcting the nutritional deficiencies the disease creates. Curcumin (the active compound in turmeric) has demonstrated anti-inflammatory effects through NF-κB pathway inhibition in multiple clinical trials, with studies showing improved remission maintenance when used alongside conventional therapy. Boswellia serrata inhibits 5-lipoxygenase and has shown results comparable to mesalamine in some trials for colonic Crohn’s.

L-glutamine is the primary fuel source for enterocytes (intestinal lining cells) and supports mucosal repair and tight junction integrity. Zinc carnosine and collagen peptides support intestinal barrier restoration. Omega-3 fatty acids (EPA and DHA from fish oil) have demonstrated modest benefit in reducing inflammatory cytokines and supporting remission, particularly at doses of 3–4g daily. Vitamin D3 supplementation at optimising levels (typically 2,000–5,000 IU daily) is associated with reduced flare risk and is almost universally depleted in Crohn’s patients.

Saccharomyces boulardii, a non-pathogenic yeast probiotic, has the strongest evidence base among probiotics for Crohn’s, reducing relapse rates in multiple trials. Critically, supplementation should be guided by testing and always coordinated with your physician, particularly if you are on immunosuppressants or biologics where interactions must be monitored.

Ready to understand your Crohn's disease?

At Patients Medical, we combine the most advanced functional medicine testing with expert physician interpretation to identify the specific drivers of your Crohn’s disease — and build a precision protocol to achieve and sustain remission on your terms.

Call us at (212) 794-8800 · 800 Second Avenue, Suite 900, New York, NY 10017

Begin Your Journey with Patients Medical

Patients Medical specializes in gently helping the patient identify the root cause of their medical issues and then assist them to recover from their problems to help them move forward to good health.

Request your consultation today!

To schedule an in person on Tele-medicine appointment, please call our office at (212) 794-8800 or email us at info@PatientsMedical.com We look forward to hearing from you

Our medical center in New York City.

Patients Medical PC
1148 Fifth Avenue, Suite 1B New York, NY 10128

Make an Appointment

TreatmentsTesting

Please leave this field empty.